Accruals

This page provides figures for ‘accruals’ or the number of people ‘recruited’ to cancer trials in Ireland. 

Note: While Cancer Trials Ireland makes every effort to track numbers for all trials in Ireland, in some instances this is not possible. The figures below therefore are accurate for 95%+ of all trials in Ireland.

WARNING: If you are not working in the cancer trials community, you should not interpret the figures below without assistance from Cancer Trials Ireland. While COVID19 and the Ransomware attack have impacted the number of patients recruited to trials, there may be other factors contributing to a decrease/increase in recruitment. 

What are the latest figures?

The figures below relate to the full years of 2023, 2022, and 2021 from January 1st – December 31st. They include every type of trial, Clinical Trials (interventional / drug trials / combination drug and radiotherapy trials), radiotherapy trials, medical devices, translational trials (biomarker and observational studies) and registries. The numbers also include academic and industry trials. The data for the same period in 2022 & 2021 is included for comparative purposes.  

Twelvemonths of the Year: Below numbers reflect patients newly recruited to cancer clinical trials in Ireland

*RT/IMP, RT/IMP involv and Med Dev/RT involv categories were introduced in 2022 (all above numbers have been revised accordingly)

What does ‘CTRIAL’ mean?

This refers to studies that have a Cancer Trials Ireland code, because it is a study in which we play an active part, or because it is a study we have ‘adopted’ into our portfolio, in order to include it in DSSG meeting discussions, and for other reasons. 

What does ‘Non-CTRIAL’ mean? 

This refers to studies whose recruitment numbers we track, but which Cancer Trials Ireland is not involved with in any capacity. Our objective in tracking recruitment numbers on these trials, and CTRIAL trials, is to provide the fullest picture possible for the number of people joining cancer trials in Ireland.

Accruals classified by disease area:

The figures below display patient recruitments in terms of the disease area they were recruited to for the full year (all 12 months) of 2023 vs. the same period in 2022 and 2021. 

WARNING: Many complex factors contribute to the rise and fall of patient recruitment, including trial availability, trial closure, patient population and so forth. Readers should not simply interpret this data as a measure of performance.  

DSSG2023 Q1 – Q42022 Q1 – Q42021 Q1 – Q4
Basket33922689
Breast 741520720
CNS002
GI 11410632
GU14987118
Gynaecology11917
Head & Neck43248
Lung604524
Lymph & Haem263410266
Melanoma28226
Paeds212040
Sarcoma310
Total1772 14701322

* Basket trials include several different disease areas in one trial.

Accruals classified by trial site:

The figures below display patient recruitments regarding the hospital sites where they were recruited to the year of 2023 (all 12 months) versus the same period in previous years.   

WARNING: Many complex factors contribute to the rise and fall of patient recruitment, including trial availability, trial closure, patient population and so forth. Readers should not simply interpret this data as a measure of performance.  

Site2023 Q1 – Q42022 Q1 – Q42021 Q1 – Q4
BH/ OLOLH311346266
Beacon5513
BonS805019
BonS/UPMC20913
CUH123237394
LUH000
MMUH241180169
MRHT1414554
CHI202040
SJH703838
SLRON525431
SVUH29612261
SUH2911
TUH1014340
UHG118980
UHL4491153
UHW292320
Total152610451017

* Basket trials include several different disease areas in one trial.

*CTI conducted an online survey on metastatic breast cancer (MBC survey, 246 participants) which did not including clinical trials units activity.